checkAd

    DGAP-News  644  0 Kommentare Sangui BioTech International Inc.: Revenues of USD 67,000 in fiscal year 2017; Granulox license income increased by 37%





    DGAP-News: Sangui BioTech International Inc. / Key word(s): Development of Sales


    Sangui BioTech International Inc.: Revenues of USD 67,000 in fiscal year 2017; Granulox license income increased by 37%


    18.07.2017 / 13:26



    The issuer is solely responsible for the content of this announcement.



    Sangui BioTech:




    - Revenues of USD 67,000 in fiscal year 2017;
    - Granulox license income increased by 37%.


    Witten, July 18, 2017



    According to preliminary unaudited figures, Sangui BioTech International Inc. achieved revenues in the amount of approximately USD 67,000 from license fees in the course of its financial year 2017 (as of June 30, 2017). Due to increased revenues of the wound spray Granulox the resulting licensing income could be increased by 37% compared to the previous year. Both revenues in the first and second half of the year were significantly higher than in the corresponding prior-year periods. After a decline in sales in the third quarter as a result of the good year-end business in the second quarter, sales of Granulox rose by 58% in the fourth quarter.





    While the 2016 financial year was characterized by declining sales due to a lack of comprehensive reimbursement in Germany, this trend was more than compensated for by the increase in sales in other sales areas in the financial year just ended. As a result of the reimbursement achieved in 2016 in the Netherlands and Great Britain, Granulox sales in these countries were already 20% higher than in 2016 for the period from January to June 2017. The market in Mexico continues to be very pleasing. Here, the inclusion of Granulox in the list of hospitals available products (Cuaro basico) led to increasing demand. Increasing sales are also reported from Poland: a recent study published in Poland in patients with venous ulcers supported the efforts of the Polish sales partner.

    Seite 1 von 2


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News Sangui BioTech International Inc.: Revenues of USD 67,000 in fiscal year 2017; Granulox license income increased by 37% DGAP-News: Sangui BioTech International Inc. / Key word(s): Development of Sales Sangui BioTech International Inc.: Revenues of USD 67,000 in fiscal year 2017; Granulox license income increased by 37% 18.07.2017 / 13:26 The issuer is solely …